NLS Agreement

Boehringer Ingelheim and Saniona, a Nordic biotech company in the field of ion channel drug discovery, today announced that they have entered into a research collaboration with the objective to discover and develop novel compounds for the treatment of schizophrenia. Saniona may receive up to €90 million in milestone payments including an upfront payment of […]

SARomics Biostructures has entered into a collaborative distributorship agreement with Carna Biosciences to provide its crystallography and protein structure determination services in Japan. Under the terms of the agreement, Carna Biosciences will be the exclusive distributor for SARomics’ co-crystallography services on the Japanese market. The agreement also encompasses non-exclusive distribution in China, Korea, Canada and the state of California. The crystallography […]

Albumedix and Hebei Changshan Biochem Pharma announced before the summer that they have entered into a supply agreement for the development of a novel type II diabetes treatment that enables once-weekly dosing. The agreement will see Albumedix’s recombinant albumin based half-life extension platform used for the development and later commercialization of a modified glucagon-like-peptide albumin […]

Genmab has entered an agreement to grant Gilead Sciences, an exclusive license and an option on a second exclusive license, to use the DuoBody technology platform to create and develop bispecific antibody candidates for a therapeutic program targeting HIV. Under the terms of the agreement, Genmab will receive an upfront payment of USD 5 million […]

Diamyd’s associated company Cellaviva has signed an agreement regarding the European distribution rights for a stem cell product developed by StemBioSys, a privatetly held biomedical company based in Texas, USA. The agreement entails that Cellaviva becomes the exclusive distributor for StemBioSys’ products in Sweden and Denmark with non-exclusive rights covering the rest of Europe. The […]

Sprint Bioscience and the US drug development company Petra Pharma Corporation have entered into a collaboration and license agreement for the research, development, and commercialization of Sprint Bioscience’s PIP4K2a program targeting tumor metabolism. Under the agreement, Sprint Bioscience licenses a PIP4k2a inhibitor program targeting tumor metabolism to the US company. Subsequently, the US company will […]